专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2018044640A1 ANTI-GREMLIN-1 (GREM1) ANTIBODIES AND METHODS OF USE THEREOF FOR TREATING PULMONARY ARTERIAL HYPERTENSION 审中-公开
标题翻译：抗GREMLIN-1（GREM1）抗体及其用于治疗肺动脉高血压的方法
公开(公告)号：WO2018044640A1
公开(公告)日：2018-03-08
申请号：PCT/US2017/048137
申请日：2017-08-23
申请人： REGENERON PHARMACEUTICALS, INC.
发明人： CHALOTHORN, Dan , MORTON, Lori C.
IPC分类号： C07K16/24 , A61K39/00
摘要： The present invention provides anti-Gremlin-1 (GREM1) antibodies, and antigen-binding fragments thereof, as well as methods of use of such antibodies, or antigen-binding fragments thereof, for treating a subject having pulmonary arterial hypertension (PAH). It is disclosed a method of treating a subject having pulmonary arterial hypertension (PAH), comprising administering to the subject a therapeutically effective amount of an anti-gremlin-1 (GREM1) antibody, or antigen-binding fragment thereof, wherein the therapeutic effect of administration of the anti-GREMl antibody, or antigen-binding fragment thereof, to the subject is selected from the group consisting of inhibiting thickening of the pulmonary artery in the subject; increasing stroke volume in the subject; increasing right ventricle cardiac output in the subject; and extending survival time of the subject, thereby treating the subject having PAH.
摘要翻译：本发明提供了抗Gremlin-1（GREM1）抗体及其抗原结合片段，以及使用这些抗体或其抗原结合片段用于治疗患有肺动脉高压（PAH）的受试者的方法。公开了治疗患有肺动脉高压（PAH）的受试者的方法，该方法包括给予受试者治疗有效量的抗Gremlin-1（GREM1）抗体或其抗原结合片段，其中治疗效果为向受试者施用抗GREM1抗体或其抗原结合片段选自：抑制受试者中肺动脉增厚; 增加受试者的每搏输出量; 增加受试者的右心室心输出量; 并延长受试者的存活时间，从而治疗患有PAH的受试者。

2. 发明申请

WO2017015472A1 ANTIGEN-BINDING PROTEINS TO MARINOBUFAGENIN 审中-公开
标题翻译：抗原结合蛋白到马林布格宁
公开(公告)号：WO2017015472A1
公开(公告)日：2017-01-26
申请号：PCT/US2016/043360
申请日：2016-07-21
申请人： REGENERON PHARMACEUTICALS, INC.
发明人： DUNN, Michael , MORTON, Lori C. , RAY, Yonaton , KIM, Jee H.
IPC分类号： C07K16/26 , A61K39/00
CPC分类号： C07K16/26 , A61K2039/505 , A61K2039/54 , A61K2039/545 , C07K2317/21 , C07K2317/76 , C07K2317/90 , C07K2317/92 , C07K2317/94
摘要： The present invention provides monoclonal antigen-binding proteins that bind to the cardiac glycoside marinobufagenin (MBG), and methods of use. In various embodiments of the invention, the antigen-binding proteins are fully human antigen-binding proteins that bind to MBG. In some embodiments, the antigen-binding proteins of the invention are useful for inhibiting or neutralizing MBG activity, thus providing a means of treating or preventing a MBG-associated disease or disorder selected from the group consisting of hypertension, myocardial fibrosis, uremic cardiomyopathy, heart failure, myocardial infarction, renal failure, renal fibrosis and pre-eclampsia.
摘要翻译：本发明提供了结合强心苷甙蛋白原基因（MBG）的单克隆抗原结合蛋白及其使用方法。在本发明的各种实施方案中，抗原结合蛋白是与MBG结合的完全人抗原结合蛋白。在一些实施方案中，本发明的抗原结合蛋白可用于抑制或中和MBG活性，从而提供治疗或预防选自以下的MBG相关疾病或病症的方法：高血压，心肌纤维化，尿毒症性心肌病，心力衰竭，心肌梗塞，肾衰竭，肾纤维化和先兆子痫。

3. 发明公开

EP4059520A1 ANTI-ACTIVIN A ANTIBODIES AND USES THEREOF 审中-公开
公开(公告)号：EP4059520A1
公开(公告)日：2022-09-21
申请号：EP22171327.4
申请日：2014-07-30
申请人： Regeneron Pharmaceuticals, Inc.
发明人： GROMADA, Jesper , LATRES, Esther , MURPHY, Andrew J. , YANCOPOULOS, George D. , MORTON, Lori C.
IPC分类号： A61K39/395 , C07K16/22 , A61K39/00 , A61P3/00 , A61P3/04 , A61P3/10 , A61P19/02 , A61P19/10 , A61P21/00 , A61P21/02 , A61P21/04 , A61P21/06 , A61P25/00 , A61P25/16 , A61P35/00 , A61P43/00
摘要： The present invention provides antibodies that bind to Activin A and methods of using the same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to Activin A with high affinity. The antibodies of the invention are useful for the treatment of diseases and disorders characterized by decreased muscle mass or strength, such as sarcopenia, cachexia, muscle injury, muscle wasting/atrophy, cancer, fibrosis, and weight loss. The antibodies of the invention are also useful in combination with GDF8 binding proteins for the treatment of diseases and disorders characterized by decreased muscle mass or strength. The antibodies of the invention are also useful for the prevention, treatment, or amelioration of disorders and diseases caused by, promoted by, exacerbated by, and/or aggravated by Activin A, such as renal fibrosis.

4. 发明公开

EP3730151A1 ANTI-ACTIVIN A ANTIBODIES AND USES THEREOF 审中-公开
公开(公告)号：EP3730151A1
公开(公告)日：2020-10-28
申请号：EP20176858.7
申请日：2014-07-30
申请人： Regeneron Pharmaceuticals, Inc.
发明人： GROMADA, Jesper , LATRES, Esther , MURPHY, Andrew J. , YANCOPOULOS, George D. , MORTON, Lori C.
IPC分类号： A61K39/395 , C07K16/22 , A61K39/00 , A61P3/00 , A61P3/04 , A61P3/10 , A61P19/02 , A61P19/10 , A61P21/00 , A61P21/02 , A61P21/04 , A61P21/06 , A61P25/00 , A61P25/16 , A61P35/00 , A61P43/00
摘要： The present invention provides antibodies that bind to Activin A and methods of using the same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to Activin A with high affinity. The antibodies of the invention are useful for the treatment of diseases and disorders characterized by decreased muscle mass or strength, such as sarcopenia, cachexia, muscle injury, muscle wasting/atrophy, cancer, fibrosis, and weight loss. The antibodies of the invention are also useful in combination with GDF8 binding proteins for the treatment of diseases and disorders characterized by decreased muscle mass or strength. The antibodies of the invention are also useful for the prevention, treatment, or amelioration of disorders and diseases caused by, promoted by, exacerbated by, and/or aggravated by Activin A, such as renal fibrosis.

5. 发明公开

EP3027209A1 ANTI-ACTIVIN A ANTIBODIES AND USES THEREOF 有权
标题翻译：安东尼奥GEGEN ACTIVIN A UND VERWENDUNGEN DAVON
公开(公告)号：EP3027209A1
公开(公告)日：2016-06-08
申请号：EP14750421.1
申请日：2014-07-30
申请人： Regeneron Pharmaceuticals, Inc.
发明人： GROMADA, Jesper , LATRES, Esther , MURPHY, Andrew J. , YANCOPOULOS, George D. , MORTON, Lori C.
IPC分类号： A61K39/395 , C07K16/22
摘要： The present invention provides antibodies that bind to Activin A and methods of using the same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to Activin A with high affinity. The antibodies of the invention are useful for the treatment of diseases and disorders characterized by decreased muscle mass or strength, such as sarcopenia, cachexia, muscle injury, muscle wasting/atrophy, cancer, fibrosis, and weight loss. The antibodies of the invention are also useful in combination with GDF8 binding proteins for the treatment of diseases and disorders characterized by decreased muscle mass or strength. The antibodies of the invention are also useful for the prevention, treatment, or amelioration of disorders and diseases caused by, promoted by, exacerbated by, and/or aggravated by Activin A, such as renal fibrosis.
摘要翻译：本发明提供了结合活化素A的抗体及其使用方法。根据本发明的某些实施方案，抗体是以高亲和力结合活化素A的完全人抗体。本发明的抗体可用于治疗特征为肌肉质量或强度降低的疾病和病症，例如肌肉减少症，恶病质，肌肉损伤，肌肉消瘦/萎缩，癌症，纤维化和体重减轻。本发明的抗体也可与GDF8结合蛋白结合用于治疗以肌肉质量或强度降低为特征的疾病和病症。本发明的抗体也可用于预防，治疗或改善由激活素A如肾纤维化引起，加重和/或恶化引起的疾病和疾病。

6. 发明公开

EP4062937A1 ANTI-ACTIVIN A ANTIBODIES AND USES THEREOF 审中-公开
公开(公告)号：EP4062937A1
公开(公告)日：2022-09-28
申请号：EP22171329.0
申请日：2014-07-30
申请人： Regeneron Pharmaceuticals, Inc.
发明人： GROMADA, Jesper , LATRES, Esther , MURPHY, Andrew J. , YANCOPOULOS, George D. , MORTON, Lori C.
IPC分类号： A61K39/395 , C07K16/22 , A61K39/00 , A61P3/00 , A61P3/04 , A61P3/10 , A61P19/02 , A61P19/10 , A61P21/00 , A61P21/02 , A61P21/04 , A61P21/06 , A61P25/00 , A61P25/16 , A61P35/00 , A61P43/00
摘要： The present invention provides antibodies that bind to Activin A and methods of using the same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to Activin A with high affinity. The antibodies of the invention are useful for the treatment of diseases and disorders characterized by decreased muscle mass or strength, such as sarcopenia, cachexia, muscle injury, muscle wasting/atrophy, cancer, fibrosis, and weight loss. The antibodies of the invention are also useful in combination with GDF8 binding proteins for the treatment of diseases and disorders characterized by decreased muscle mass or strength. The antibodies of the invention are also useful for the prevention, treatment, or amelioration of disorders and diseases caused by, promoted by, exacerbated by, and/or aggravated by Activin A, such as renal fibrosis.

7. 发明授权

EP3027209B1 ANTI-ACTIVIN A ANTIBODIES AND USES THEREOF 有权
公开(公告)号：EP3027209B1
公开(公告)日：2020-09-02
申请号：EP14750421.1
申请日：2014-07-30
申请人： Regeneron Pharmaceuticals, Inc.
发明人： GROMADA, Jesper , LATRES, Esther , MURPHY, Andrew J. , YANCOPOULOS, George D. , MORTON, Lori C.
IPC分类号： A61K39/395 , C07K16/22

8. 发明公开

EP3504238A1 ANTI-GREMLIN-1 (GREM1) ANTIBODIES AND METHODS OF USE THEREOF FOR TREATING PULMONARY ARTERIAL HYPERTENSION 审中-公开
公开(公告)号：EP3504238A1
公开(公告)日：2019-07-03
申请号：EP17761986.3
申请日：2017-08-23
申请人： Regeneron Pharmaceuticals, Inc.
发明人： CHALOTHORN, Dan , MORTON, Lori C.
IPC分类号： C07K16/24 , A61K39/00

9. 发明公开

EP3325507A1 ANTIGEN-BINDING PROTEINS TO MARINOBUFAGENIN 审中-公开
公开(公告)号：EP3325507A1
公开(公告)日：2018-05-30
申请号：EP16745361.2
申请日：2016-07-21
申请人： Regeneron Pharmaceuticals, Inc.
发明人： DUNN, Michael , MORTON, Lori C. , RAY, Yonaton , KIM, Jee H.
IPC分类号： C07K16/26 , A61K39/00
CPC分类号： C07K16/26 , A61K2039/505 , A61K2039/54 , A61K2039/545 , C07K2317/21 , C07K2317/76 , C07K2317/90 , C07K2317/92 , C07K2317/94
摘要： The present invention provides monoclonal antigen-binding proteins that bind to the cardiac glycoside marinobufagenin (MBG), and methods of use. In various embodiments of the invention, the antigen-binding proteins are fully human antigen-binding proteins that bind to MBG. In some embodiments, the antigen-binding proteins of the invention are useful for inhibiting or neutralizing MBG activity, thus providing a means of treating or preventing a MBG-associated disease or disorder selected from the group consisting of hypertension, myocardial fibrosis, uremic cardiomyopathy, heart failure, myocardial infarction, renal failure, renal fibrosis and pre-eclampsia.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式